Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria
K. Kiga, X.-E. Tan, R. Ibarra-Chavez, S. Watanabe, Y. Aiba, Y. Sato, F.-Y. Li, T. Sasahara, B. Cui, M. Kawauchi, T. Boonsiri, K. Thitiananpakorn, Y. Taki, A. H. Azam, M. Suzuki, , L. Cui
This study develops CRISPR-Cas13a-based antimicrobials that kill target bacteria by cleaving RNA, showing effectiveness against carbapenem-resistant E. coli and methicillin-resistant S. aureus.
bioRxiv · Nov 18, 2019Microbiology